CHICAGO, IL—The pool of patients who could potentially benefit from a glucagon-like peptide 1 (GLP-1) receptor agonist has expanded, thanks to new data showing that people with diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback